U.S. lawmakers attempting to cut the cost of insulin for more than a million Americans to $35 per month are unlikely to succeed as November elections draw near and complicate bipartisan support, health policy and political experts say.
Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.
Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.
Novo Nordisk said the world’s top maker of diabetes drugs will lay off 400 staff in Denmark and China as part of a broader restructuring of the company’s research and development organization.
